Table of Contents

Editorial 1. Can Nonpharmacological Agents Decrease Cardiovascular Diseases, without Decreasing Serum Cholesterol?
Ram B Singh, Galal Elkilany, Osama Elmarghy, Jan Fedacko, and Krasimira Hristova

Editorial 2. Can Twin Incretins Decrease Blood Glucose and Blood Lipids?
R B Singh, Osama Elmarghi, Galal Elkilany, Jan Fedacko, and Gushchina Yulia

View Point. Glucagon Like Peptide-1 Levels and Its Variability
Galal Elkilany, Ram B Singh, Osama Elmarghi, Jan Fedacko, Narsingh Verma, Anuj Maheshwari, Saibal Chakravorty, and Germaine Cornelissen

Usage of Serum Anion Gap to Predict in-Hospital and 1-Year All-Cause Mortality in Cardiac Care Unit Patients
Thanapon Nilmoje, Saranyou Suwanugsorn, Wisanuwee Suriyaamorn, Ittipon Preechawettayakul, Veerapong Vattanavanit, and Ply Chichareon

The Use of Statins in Primary Prevention of Cardiovascular Disease: Benefits versus Risks
Adji Prayitno Setiadi, Sylvi Irawati, Bobby Presley, Eko Setiawan, and Yosi Irawati Wibowo

Incidental Findings of Brugada Syndrome Type-1 and Epsilon-Like Pattern in Otherwise Healthy Man: A Case Report
Brian Mendel, Kelvin Kohar, Karen Elliora Utama, Valerie Josephine Dirjayanto, Radityo Prakoso, and Sisca Natalia Siagian

Glucagon Like Peptide Agonists as Therapy for Treatment of Cardiometabolic Diseases
R B Singh, Mahmood Moshiri, Osama Elmarghi, Galal elkilany, Jan Fedacko, and Gushchina Yulia

Impact of Time Delay on Thrombus Burden and TIMI-Flow in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention
Khaled Abdelgaber Abozeid, Ahmed Farouk Alaarag, Timoor Mostafa Abdallah, and Mai Mohamed Salama

Personalized Medicine: A Novel Approach for the Management of Hypertension
Ghizal Fatima and Farzana Mahdi